Xention Extends Pact with Ono

The firms extended an agreement under which Xention is using its ion channel drug discovery platform to identify, design, and synthesize small molecules against ion channels chosen by Ono.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.